| Drug ID: | Drug52 |
|---|---|
| Drug Name: | Iron |
| CID: | 23925 |
| DrugBank ID: | DB01592 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | NO |
| Other Approved: | YES |
| Identifier: | NCT01017614, , NCT03441893 |
| Molecular Formula: | Fe |
| Molecular Weight: | 55.84 g/mol |
| Isomeric SMILES: | [Fe] |
| Synonyms: | IRON; 7439-89-6; Iron, elemental; Ferrum; Iron powder; Remko; Armco iron; Ferrovac E; Ancor B; hierro |
| Phase 0: | 4 |
| Phase 1: | 19 |
| Phase 2: | 46 |
| Phase 3: | 81 |
| Phase 4: | 92 |
| Description: | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt472 | 23925 | Iron | 3040 | HBA2 | Homo sapiens (human) | Activator | |
| dt473 | 23925 | Iron | 7037 | TFRC | Homo sapiens (human) | 16564538 | None |
| dt474 | 23925 | Iron | 54583 | EGLN1 | Homo sapiens (human) | 16649251 | None |
| dt475 | 23925 | Iron | 55869 | HDAC8 | Homo sapiens (human) | 16681389 | Cofactor |
| dt476 | 23925 | Iron | 51327 | AHSP | Homo sapiens (human) | 16901899 | None |
| dt477 | 23925 | Iron | 2395 | FXN | Homo sapiens (human) | 16911956 | None |
| dt478 | 23925 | Iron | 2495 | FTH1 | Homo sapiens (human) | 17070541 | None |
| dt479 | 23925 | Iron | 2237 | FEN1 | Homo sapiens (human) | 20622253 | None |
| dt480 | 23925 | Iron | 79661 | NEIL1 | Homo sapiens (human) | 20622253 | None |
| dt481 | 23925 | Iron | 252969 | NEIL2 | Homo sapiens (human) | 20622253 | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06321887 | EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD | PHASE3 | RECRUITING | Liverpool University Hospitals NHS Foundation Trust | Inflammatory Bowel Disease|Iron Deficiency Anemia | DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… | Details |
| NCT01438372 | IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD | PHASE2 | WITHDRAWN | Wayne State University | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Intravenous iron sucrose|DRUG: Oral ferrous… | Details |
| NCT02774057 | Trial of Captafer vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD | PHASE4 | UNKNOWN | American University of Beirut Medical Center | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Captafer|DRUG: Iron Sulfate | Details |
| NCT02760940 | Anemia in Inflammatory Bowel Disease | PHASE4 | UNKNOWN | Federal University of Juiz de Fora | Anemia|Bowel Diseases, Inflammatory | DRUG: oral liposomal iron | Details |
| NCT03376230 | Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease | None | TERMINATED | University Hospital, Lille | Inflammatory Bowel Diseases | OTHER: Collect of blood, urines, and intestinal b… | Details |
| NCT03457571 | Clinical Observational Study: IBD Patients With Restless-legs-syndrome and Iron Deficiency Syndrome | None | COMPLETED | Charite University, Berlin, Germany | Inflammatory Bowel Diseases|Restless Legs Syndrom… | None | Details |
| NCT00810030 | FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR | PHASE3 | COMPLETED | Vifor Pharma | Inflammatory Bowel Disease|Anemia|Iron Deficiency… | DRUG: Ferric carboxymaltose|DRUG: Iron Sucrose | Details |
| NCT06120322 | Machine Learning Approach to Study the Interactions Between Environment and Intestinal Tissue Homeostasis in IBD | None | NOT_YET_RECRUITING | IRCCS San Raffaele | Diabetes Mellitus, Type 1|Ulcerative Colitis | OTHER: Environmental factor monitoring; collectio… | Details |
| NCT05225545 | Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis | PHASE3 | RECRUITING | American University of Beirut Medical Center | Anemia, Iron Deficiency|Ulcerative Colitis | DRUG: Sucrosomial Iron|DRUG: Oral Iron | Details |
| NCT03282903 | The PRognostic Effect of Environmental Factors in Crohn's and Colitis | None | COMPLETED | University of Edinburgh | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | None | Details |
| NCT03247816 | Feraccru Real World Effectiveness Study in Hospital Practice ( FRESH ) | None | COMPLETED | Shield Therapeutics | Anemia, Iron Deficiency|Inflammatory Bowel Diseas… | None | Details |
| NCT01017614 | Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia | PHASE3 | COMPLETED | Pharmacosmos A/S | Inflammatory Bowel Disease | DRUG: Monofer; DRUG: Iron Sulphate | Details |
| NCT05176795 | Host-microbiota-environment Interactions | Not Available | RECRUITING | University Hospital, Clermont-Ferrand | Juvenile Idiopathic Arthritis; Diabetes type1; In… | OTHER: Stool sample | Details |
| ChiCTR2500100314 | Analysis of iron-related indexes and disease association in patients with inflammatory bowel disease | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University | Inflammatory bowel disease | IBD patients:None; | Details |
| DRKS00034606 | CEDATA GPGE Patient Registry - Registry for chronic inflammatory bowel diseases in children and adolescents - CEDATA | Not Available | Recruiting | Gesellschaft f Piatrische Gastroenterologie und Ernrung e. V. | Inflammatory Bowel Disease K50-K52;Noninfective … | Group 1: Health Care Data is entered into an onli… | Details |
| NCT02517151 | Iron Supplementation in Inflammatory Bowel Disease (IBD) Patients With Chronic Fatigue | PHASE2 | UNKNOWN | Istituto Clinico Humanitas | Chronic Fatigue|Inflammatory Bowel Disease | DRUG: Ferric carboxymaltose|DRUG: Placebo | Details |
| ACTRN12624000016538 | Longitudinal study of diet, lifestyle and biomarker predictors of pouchitis | Not Available | Not Recruiting | Monash University | Inflammatory bowel disease;familial adenomatous p… | We will be following individuals with an ileoanal… | Details |
| ChiCTR2200066959 | Study on the effect of iron supplementation on the efficacy of anti-TNF-a monoclonal antibody in patients with IBD | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Inflammatory bowel disease | Intervention group :iron isomaltoside;Control gro… | Details |
| ChiCTR2200066056 | A comparative study of iron isomaltoside versus traditional iron supplements in patients with inflammatory bowel diseases and iron deficiency anemia | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Inflammatory bowel disease | Intervention group:iron isomaltoside;Control grou… | Details |
| EUCTR2022-000894-16-NL | Predicting Response to Iron Supplementation in Patients with active Inflammatory Bowel Disease_ - PRIme | PHASE4 | Not Recruiting | Leiden University Medical Center | Inflammatory Bowel Disease MedDRA version: 20.0_… | Trade Name: Feraccru Pharmaceutical Form: Capsule… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Inflammatory bowel disease risk and the environment: Where to next?
PMID: 27240003
Year: 2016
Relationship Type:
Association
Score: 6.3
Response of Iron Deficiency Anemia to Intravenous Iron Sucrose in Pediatric Inf…
PMID: 27199624
Year: 2016
Relationship Type:
Association
Score: 6.3
Not found
Contributions of historical and contemporary geographic and environmental facto…
PMID: 27137438
Year: 2016
Relationship Type:
Association
Score: 6.3
Inflammatory bowel diseases (IBDs), which include Crohn's disease and ulcerative colitis, are inflammatory diseases of the gastrointestinal tract. Q…
Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in…
PMID: 27101422
Year: 2017
Relationship Type:
Treatment
Score: 6.3
AIM: To investigate the therapeutic effect of hydrogen-rich water (HRW) on inflammatory bowel disease (IBD) and to explore the potential mechanisms …
Identification of Environmental Factors Associated with Inflammatory Bowel Dise…
PMID: 27070313
Year: 2016
Relationship Type:
Treatment
Score: 6.3
Anxiety, depression, and altered memory are associated with intestinal diseases, including inflammatory bowel disease (IBD). Understanding the link …
Iron Deficiency in the Absence of Anemia Impairs the Perception of Health-Relat…
PMID: 27057682
Year: 2016
Relationship Type:
Treatment
Score: 6.3
Erratum in Intern Emerg Med. 2017 Feb;12 (1):141. Piacchianti Diamanti, Andrea [corrected to Picchianti Diamanti, Andrea]. Vitamin D deficiency…
Comparison of the Efficacies of Parenteral Iron Sucrose and Oral Iron Sulfate f…
PMID: 27021505
Year: 2016
Relationship Type:
Association
Score: 6.3
BACKGROUND: CT-P13 is a biosimilar drug of reference infliximab and is approved in some countries for use in some indications for which reference in…
The appropriate dose and cost of iron replacement therapy in patients with IBD
PMID: 27006185
Year: 2017
Relationship Type:
Treatment
Score: 6.3
Not found
Iron Deficiency, Zinc, Magnesium, Vitamin Deficiencies in Crohn's Disease: Subs…
PMID: 26982488
Year: 2016
Relationship Type:
Association
Score: 6.3
Recently, the field of proteomics has rapidly expanded in its application towards clinical research with objectives ranging from elucidating disease…
IBD and Environment: Are There Differences between East and West
PMID: 26982053
Year: 2016
Relationship Type:
Mechanism
Score: 6.3
Erratum in J Crohns Colitis. 2022 Aug 16;: Comment in J Crohns Colitis. 2022 Jan 24;: BACKGROUND AND AIMS: Both science and patients associ…
Environmental and Historical Determinants of Patterns of Genetic Differentiatio…
PMID: 26952904
Year: 2016
Relationship Type:
Association
Score: 6.3
Changes in the distribution and products of enteroendocrine cells may play a role in immune activation and regulation of gut inflammation. This revi…
Inflammatory Bowel Disease in Asia: A Second Chance at Uncovering Environmental…
PMID: 26930697
Year: 2016
Relationship Type:
Association
Score: 6.3
Influence of environmental factors in the development of inflammatory bowel dis…
PMID: 26855817
Year: 2016
Relationship Type:
Treatment
Score: 6.3
The intestinal microbiota plays an important role in inflammatory bowel disease (IBD). The pathogenesis of IBD involves inappropriate ongoing activa…
Oral versus intravenous iron replacement therapy distinctly alters the gut micr…
PMID: 26848182
Year: 2017
Relationship Type:
Treatment
Score: 6.3
ETHNOPHARMACOLOGICAL RELEVANCE: Inflammatory bowel disease (IBD) is generally associated with a set of debilitating symptoms including abdominal pai…
Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Dise…
PMID: 26818422
Year: 2016
Relationship Type:
Treatment
Score: 6.3
To evaluate the associations between single nucleotide polymorphisms (SNPs) of factors involved in the development of invasive bacterial disease (IB…
Genome-environment association study suggests local adaptation to climate at th…
PMID: 26777878
Year: 2016
Relationship Type:
Treatment
Score: 6.3
Functional bowel disorders (FBD), mainly irritable bowel syndrome (IBS) and functional constipation (FC, also called chronic idiopathic constipation…
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel …
PMID: 26765407
Year: 2016
Relationship Type:
Treatment
Score: 6.3
Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis…
An experimental model of colitis induced by dextran sulfate sodium from acute p…
PMID: 26744614
Year: 2016
Relationship Type:
Clinical Trial
Score: 6.3
AIM: To induce acute colitis progresses to chronicity in C57BL/6 mice by dextran sulfate sodium. BACKGROUND: Murine models are essential tools to und…
Serum Hepcidin and Iron Absorption in Paediatric Inflammatory Bowel Disease
PMID: 26733407
Year: 2016
Relationship Type:
Treatment
Score: 6.3
There are over 300 000 people in the UK affected by inflammatory bowel disease (IBD). Though vitamin D deficiency is common in patients with IBD, Na…
A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat I…
PMID: 26647917
Year: 2016
Relationship Type:
Treatment
Score: 6.3
One of the main tasks of the immune system is to discriminate and appropriately react to "danger" or "non-danger" signals. This is crucial in the g…